Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 18/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 18/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92594 | 0.86 | BRD4 (0.41) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL383981 | 0.81 | BRD4 (0.60) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL383980 | 0.81 | BRD4 (0.60) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL761490 | 0.77 | PLK1 (0.61) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL92591 | 0.77 | PLK1 (0.53) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL23766264 | 0.74 | BRD4 (0.61) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL22930157 | 0.72 | PLK1 (0.51) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL72299 | 0.70 | PLK1 (0.65) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL72298 | 0.70 | PLK1 (0.65) | BRD4PLK1PLK2PLK3 | |
| SCHEMBL12856830 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-8129387-B2 | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-22 | — | — | US | disclosed |
| WO-2008076392-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | BRD4 928/4885PLK1 33/4885PLK2 108/4885 |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | BRD4 928/4885PLK1 33/4885PLK2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.